Advertisement
Screener

Protagonist Therapeutics, Inc (PTGX) Graph

PTGX Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue $213.47M; Revenue including tax (m); Research and development $42.06M; Operating expenses $54.71M.
  • 2026-03-31: Revenue (m); Revenue including tax $56.37M; Research and development $46.74M; Operating expenses $60.02M.
  • 2025-12-31: Revenue (m); Revenue including tax $7.44M*; Research and development $46.36M*; Operating expenses $57.79M*.
  • 2025-09-30: Revenue (m); Revenue including tax $4.71M; Research and development $40.00M; Operating expenses $51.13M.

Revenue flow

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

PTGX revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Revenue$213.48MOperating expenses$54.71MOperating income$158.77MOther income, net-$81.00KResearch & development$42.06MPre-tax income$165.11MNet income$162.85M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueRevenue including taxResearch and developmentOperating expensesIncome taxNet income
2026-06-30$213.47M(m)$42.06M$54.71M$2.27M$162.85M
2026-03-31(m)$56.37M$46.74M$60.02M-$1.50M$3.78M
2025-12-31(m)$7.44M*$46.36M*$57.79M*$666.00K*-$44.38M*
2025-09-30(m)$4.71M$40.00M$51.13M$0.00-$39.34M
2025-06-30$5.55M$5.55M$37.04M$47.59M$172.00K-$34.77M
2025-03-31(m)$28.32M$35.89M$47.63M$0.00-$11.65M
2024-09-30(m)$4.67M$35.97M$46.13M-$420.00K-$33.21M
2024-06-30(m)$4.17M$33.52M$42.96M-$676.00K-$30.62M
2024-03-31(m)$254.95M$33.73M$48.64M$3.33M$207.34M
2023-09-30(m)$0.00$30.66M$38.33M$0.00-$34.10M
2023-06-30(m)$0.00$33.18M$42.35M$0.00-$38.46M
2023-03-31(m)$0.00$27.42M$36.02M$0.00-$33.73M
2022-09-30(m)$0.00$25.40M$32.30M(m)-$31.23M
2022-06-30(m)$859.00K$34.61M$42.30M(m)-$41.04M
2022-03-31(m)$25.72M$36.32M$46.83M(m)-$20.93M
2021-09-30(m)$10.29M$36.96M$44.21M$0.00-$33.80M
2021-06-30(m)$2.27M$26.43M$33.15M$0.00-$30.84M
2021-03-31(m)$6.19M$24.25M$30.21M$0.00-$24.00M
2020-09-30(m)$13.11M$15.99M$20.89M$0.00-$7.76M
2020-06-30(m)(m)$20.26M$24.43M$1.13M-$19.42M
2020-03-31(m)(m)$18.77M$23.34M$176.00K-$20.08M
2019-12-31(m)$2.72M(m)(m)(m)-$17.50M
2019-09-30(m)$4.14M$17.29M$21.31M-$102.00K-$16.41M
2019-06-30(m)(m)$19.36M$23.22M-$1.63M-$29.17M
2019-03-31(m)$1.56M$12.44M$16.21M$183.00K-$14.10M
2018-12-31(m)$2.35M(m)(m)(m)-$13.87M
2018-09-30(m)$6.12M$12.14M$15.51M$0.00-$8.73M
2018-06-30(m)$11.67M$17.73M$20.91M$0.00-$8.66M
2018-03-31(m)$10.78M$15.37M$19.01M$0.00-$7.66M
2017-12-31(m)$11.28M(m)(m)(m)-$3.05M
2017-09-30$8.78M$8.78M$11.17M$13.76M(m)-$4.83M
2017-06-30(m)(m)$12.01M$15.13M(m)-$14.98M
2017-03-31(m)(m)$11.28M$14.27M(m)-$14.10M
2016-12-31(m)(m)(m)(m)(m)-$11.25M
2016-09-30$0.00(m)$5.56M$7.14M(m)-$7.08M
2016-06-30(m)(m)$5.70M$7.09M(m)-$7.10M
2016-03-31(m)(m)$5.63M$7.04M(m)-$11.75M
2015-12-31(m)(m)(m)(m)(m)-$5.49M
2015-09-30(m)(m)$3.16M$4.02M(m)-$3.45M
2015-06-30(m)(m)$2.30M$3.08M(m)-$3.22M
2015-03-31(m)(m)(m)(m)(m)-$2.70M

Revenue and expense 6 month

Period endRevenueRevenue including taxResearch and developmentOperating expensesIncome taxNet income
2026-06-30$269.84M(m)$88.80M$114.72M$763.00K$166.63M
2025-06-30$33.87M$33.87M$72.93M$95.22M$172.00K-$46.43M
2024-06-30(m)$259.12M$67.25M$91.60M$2.65M$176.72M
2023-06-30(m)$0.00$60.60M$78.38M$0.00-$72.19M
2022-06-30(m)$26.58M$70.93M$89.14M(m)-$61.97M
2021-06-30(m)$8.45M$50.68M$63.36M$0.00-$54.84M
2020-06-30(m)(m)$39.02M$47.78M$1.30M-$39.50M
2019-06-30(m)(m)$31.80M$39.43M-$1.45M-$43.28M
2018-06-30(m)(m)$33.10M$39.92M$0.00-$16.32M
2017-06-30(m)(m)$23.29M$29.40M(m)-$29.08M
2016-06-30(m)(m)$11.32M$14.13M(m)-$18.84M
2015-06-30(m)(m)$4.48M$5.77M(m)-$5.92M

Revenue and expense 9 month

Period endRevenueRevenue including taxResearch and developmentOperating expensesIncome taxNet income
2025-09-30(m)$38.58M$112.93M$146.35M$172.00K-$85.77M
2024-09-30(m)$263.80M$103.22M$137.73M$2.23M$143.51M
2023-09-30(m)$0.00$91.26M$116.70M$0.00-$106.29M
2022-09-30(m)$26.58M$96.33M$121.44M(m)-$93.20M
2021-09-30(m)$18.74M$87.63M$107.57M$0.00-$88.64M
2020-09-30(m)$22.98M$55.02M$68.66M$1.30M-$47.26M
2019-09-30(m)(m)$49.09M$60.73M-$1.55M-$59.69M
2018-09-30(m)$28.57M$45.25M$55.43M$0.00-$25.06M
2017-09-30$8.78M$8.78M$34.46M$43.16M(m)-$33.91M
2016-09-30$0.00(m)$16.88M$21.27M(m)-$25.93M
2015-09-30(m)(m)$7.64M$9.79M(m)-$9.37M

Revenue and expense 12 month

Period endRevenue including taxResearch and developmentOperating expensesIncome taxNet income
2025-12-31$46.02M$159.29M$204.14M$838.00K-$130.15M
2024-12-31$434.43M$138.13M$181.59M$4.22M$275.19M
2023-12-31$60.00M$120.16M$153.65M$0.00-$78.96M
2022-12-31$26.58M$126.22M$157.95M$0.00-$127.39M
2021-12-31$27.36M$126.01M$153.20M$0.00-$125.55M
2020-12-31$28.63M$74.51M$93.14M$1.30M-$66.15M
2019-12-31$231.00K$65.00M$80.75M-$691.00K-$77.19M
2018-12-31$30.93M$59.50M$73.19M-$799.00K-$38.92M
2017-12-31$20.06M$46.18M$57.96M$0.00-$36.96M
2016-12-31(m)$25.70M$32.67M$0.00-$37.18M
2015-12-31(m)$11.83M$14.79M$0.00-$14.86M
2014-12-31(m)$7.46M$9.32M$0.00-$11.07M

Similar stocks

Stock NameCountryMarket CapPE Ratio
TG THERAPEUTICS, INC. (TGTX)United States$8.805B19.05
CYTOKINETICS INC (CYTK)United States$9.130B-11.86
ARROWHEAD PHARMACEUTICALS, INC. (ARWR)United States$9.331B-42.28
Praxis Precision Medicines, Inc. (PRAX)United States$7.884B-27.60
Structure Therapeutics Inc. (GPCR)United States$7.710B-53.41
Spyre Therapeutics, Inc. (SYRE)United States$7.685B-43.69
Axsome Therapeutics, Inc. (AXSM)United States$10.274B-66.82
IONIS PHARMACEUTICALS INC (IONS)United States$7.277B-23.25
Alkermes plc. (ALKS)$6.844B132.74
RHYTHM PHARMACEUTICALS, INC. (RYTM)United States$6.771B-37.20